Ruti Aga's Six-Year Ban: A Forged Prescription Destroyed the One Defence That Might Have Worked

The Athletics Integrity Unit statement landed on Thursday with two numbers in it: two years, four years. Together, six. Ruti Aga, Ethiopia's 32-year-old marathoner who won Tokyo in 2026, had been provisionally suspended from 10 September — and 10 September is now the first day of a six-year ban. The document at the centre of this case is not a sample report. It is a prescription for a knee, written by a family member presenting himself as a doctor on an 'old prescription pad from a former workplace'. The clinic named on that pad does not exist. The institution the pad was traced to has disowned it. Three independent verifications, three failures. The AIU established the forgery from that triple denial, not from a forensic laboratory. That is the character of the whole case. Now the point the original reporting blurred. Methylprednisolone was described as a 'prohibited steroid', 'classed as performance enhancing by WADA'. That is an incomplete account, and the case turns on the gap. Methylprednisolone is not an anabolic steroid. It is a glucocorticoid — class S9 on the WADA Prohibited List. S9 substances are prohibited in-competition only, by injection, oral or rectal route. A knee injection administered out of competition is entirely lawful treatment. The case was never about steroids. It was about route and timing. That distinction was the one real defence available. Berlin 2026, 2:18:34 for second. Tokyo 2026, 2:20:40 to win. Three runner-up finishes at World Marathon Majors. I keep a file on every knee, and the file always starts with a question. In Aga's file the question is not why she took the injection. It is why she felt she needed a receipt for it. In March she won a half marathon in China. No mark from that race appears anywhere in the reporting — no time, no splits, no field quality. The sample collected there came back positive. On the roads the in-competition window opens at 23:59 the night before the race, so an injection given days earlier is still caught. No agent and no physio is unaware of that. The arithmetic is clean. Two years for presence, the standard outcome for that class of substance where intent is not proven. Four for tampering, the standard Code sanction. Six. What the arithmetic shows is that the panel refused the no-significant-fault mitigation that would have cut the presence sanction, and, while reading the forged prescription as evidence of concealment, did not use it to aggravate. Both components are internally consistent. The sum is a sanction aimed at paperwork more than at pharmacology. Here is the turn that separates this from another doping item. What would a competent defence have achieved? Nothing forged. The actual treatment records, the injection date, the route used, the washout period prescribed for that route. With those four things the presence charge could have been argued at the no-fault end. In the best case — documented treatment, injection route, out-of-competition timing — there would have been no case at all, and no tampering charge in the file. Aga destroyed the defence that might have worked. The forgery did not spare her a sanction; it doubled one. From there the statement goes quiet. The 'doctor' was an unregistered family member. No credentialed team physician, no TUE process, no document trail. A 2:18-class marathoner whose name commands appearance fees on the Chinese label circuit is dependent on her own family for the paperwork of a knee injection. That is a governance vacuum, not a personal lapse. I came for the economics; I stayed for the medicals. The Chinese half-marathon circuit is the between-Majors income tier for East African marathoners: few races, good fees, low risk. It is also now the AIU's highest-yield testing ground. The fee economy and the testing economy are colliding in the same races. One more thing athletics does not say loudly: six years for a glucocorticoid. There is no established endurance benefit — pain falls, inflammation falls, performance does not documentably rise. Some EPO cases have drawn less. The comparison is simultaneously evidence of AIU rigour and evidence of disproportionate enforcement against African road runners. Both readings hold, and that discomfort is the case's real legacy. The enforcement frontier is moving from detection to document verification. When one informal medical network serves many athletes in the same training cluster, these cases do not arrive singly. Aga's file names a family member. No agent is named. Whoever advised her is nowhere in the record. Six years from 10 September. She will be 38 on return. Ethiopia's women's marathon depth does not automatically select a 2:18 performer; a 38-year-old with a doping record is not selectable at all. The 2026 Tokyo title stays on the record, because results before March are not automatically annulled — but the money, fees and ranking points after it went out with the document she had made. A CAS window will open, typically about 21 days from the reasoned decision. A document-based forgery finding is hard to overturn. The question is not whether Aga returns. It is who told the family member to write that prescription — and that answer is not in any file.